TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the clinical team leading the upcoming investigator-led trial, titled “Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin” (PONTiAK), has received a No Objection Letter (NOL) from Health Canada to proceed with the trial. PONTiAK is a 700-patient Phase II trial (revised from 900 patients) evaluating the efficacy of cilastatin in preventing AKI caused by several drugs, including certain antibiotics, chemotherapeutic agents, and radiographic contrast. The PONTiAK ...

February 03, 2025 07:45 ET  | Source: Arch Biopartners TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $57,246.57 in interest accrued up to February 1, 2025 on the one remaining deferred convertible note outstanding and disclosed in the Company’s financial statements for the year ended September 30, 2024 (the “Note”). The shares for debt settlement is pending final approval from the ...

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics Board, through the Clinical Trials Ontario Streamlined Research Ethics Review System, has granted provincial ethics approval for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical teams at Toronto General Hospital and St. Michael’s Hospital in Toronto are now seeking final internal approvals and completing final preparations to begin ...